Perrigo OTC Brand Journey Detours Into Management, Operating Problems
This article was originally published in The Tan Sheet
Executive Summary
The firm's report of problems in its European branded product business during its earnings briefing prompted a sharp dip in its share price, closing down more than 10% at $130.40, and left analysts looking for its private label OTC business to continue as its growth driver.